Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy

Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadzadehfar, Hojjat, Schlolaut, Stephan, Fimmers, Rolf, Yordanova, Anna, Hirzebruch, Stefan, Schlenkhoff, Carl, Gaertner, Florian C., Awang, Zool Hilmi, Hauser, Stefan, Essler, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732715/
https://www.ncbi.nlm.nih.gov/pubmed/29262549
http://dx.doi.org/10.18632/oncotarget.21600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732715/
https://www.ncbi.nlm.nih.gov/pubmed/29262549
http://dx.doi.org/10.18632/oncotarget.21600

Ejemplares similares